JPMorgan Chase & Co.'s Rating of Alnylam Pharmaceuticals on 11/18/2026

On November 18, 2026, JPMorgan Chase & Co. updated its outlook on Alnylam Pharmaceuticals (NASDAQ:ALNY) with the action "Set Price Target", setting a price target of $254.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from JPMorgan Chase & Co.

DateCompanyAction
11/19/2026
Crh Plc stock logo
CRH
CRH
Lower Price Target
11/19/2026
Septerna, Inc. stock logo
SEPN
Septerna
Boost Price Target
11/19/2026
Zai Lab Limited Unsponsored ADR stock logo
ZLAB
Zai Lab
Boost Price Target
11/19/2026
ADRX
ADARx Pharmaceuticals
Lower Price Target
11/19/2026
Amrize Ltd stock logo
AMRZ
Amrize
Lower Price Target
11/19/2026
Eagle Materials Inc stock logo
EXP
Eagle Materials
Lower Price Target
More Ratings From JPMorgan Chase & Co.